5 Stocks Pushing The Drugs Industry Downward

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 31 points (0.2%) at 15,006 as of Tuesday, July 2, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,611 issues advancing vs. 1,325 declining with 103 unchanged.

The Drugs industry currently sits up 0.4% versus the S&P 500, which is up 0.4%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. Achillion Pharmaceuticals ( ACHN) is one of the companies pushing the Drugs industry lower today. As of noon trading, Achillion Pharmaceuticals is down $2.05 (-24.5%) to $6.31 on heavy volume. Thus far, 8.3 million shares of Achillion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $6.30-$6.72 after having opened the day at $6.58 as compared to the previous trading day's close of $8.36.

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on the development of antivirals for the treatment of chronic hepatitis C viral (HCV) infection. Achillion Pharmaceuticals has a market cap of $789.8 million and is part of the health care sector. Shares are up 2.1% year to date as of the close of trading on Monday. Currently there are 9 analysts that rate Achillion Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Achillion Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow, deteriorating net income, poor profit margins and feeble growth in its earnings per share. Get the full Achillion Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Achillion Shares Are Plunging on Termination of Hepatitis C Pact

Achillion Pharmaceuticals Stock Falls, Baird Downgrades Over Lack of Confidence